MOTS-c Liquid Spray · Research brief

Best Time to Take MOTS-c: Morning or Night Research

Real Peptides Research TeamEditorial

Updated September 25, 20269 min read

40 WORDS

Short answer

The most influential MOTS-c experiments in the published literature were run on nocturnal rodents handled during the lab's working hours, which is the animal's sleep phase. That single detail quietly dismantles most of the morning-versus-night argument circulating about this peptide.

Key takeaways

There is no established best time to take MOTS-c, because no published head-to-head human trial has compared morning against night administration.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA, characterised in Cell Metabolism in 2015.
The mechanistic reason timing is discussed at all is that AMPK activity and NAD+ availability oscillate across a 24-hour cycle, not that the peptide behaves differently at different hours.
Rodents are nocturnal, so a light-phase experiment reported as morning corresponds physiologically to a human sleep phase, which makes naive cross-study timing comparisons unreliable.
Zeitgeber time (ZT0 as lights-on) is the notation that makes circadian phase reproducible between facilities, including those running reversed light cycles.
Lyophilised MOTS-c stored at -20C, protected from light, and spared repeated freeze-thaw cycles is the baseline condition for any timing experiment producing interpretable data.
Real Peptides supplies research-use-only MOTS-c with batch-specific certificates of analysis and provides no dosing, timing, or preparation guidance to anyone.

Our team supplies research-grade MOTS-c to labs studying mitochondrial metabolism, and the timing question arrives constantly, usually phrased as MOTS-c morning or night, as though a settled answer exists. It doesn't. What exists is a body of chronobiology work explaining why time-of-day is a variable worth controlling in a study design.

'What is the best time to take MOTS-c?'

There is no established best time to take MOTS-c. MOTS-c is a research-use-only compound, and Real Peptides provides no administration or timing guidance. The literature does show that AMPK, the enzyme MOTS-c acts upstream of, follows a circadian rhythm, which is why published study designs record time-of-day as a controlled condition rather than a detail.

The common oversimplification is that the timing debate is about the peptide. It isn't. Circadian variation sits in the host's metabolic state (NAD+ availability, AMPK tone, substrate oxidation), not in the molecule, whose chemistry is identical at 6am and 10pm. This piece covers the mitochondrial rhythms behind the best time to take MOTS-c question, what published study designs actually report about time-of-day, and how handling and identity verification decide whether any timing result means anything.

Mitochondrial rhythms are the real subject of the timing question

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide of roughly 2.2 kDa encoded inside mitochondrial DNA rather than the nuclear genome, first characterised in a 2015 Cell Metabolism paper from Pinchas Cohen's research group. Its best-described mechanism is indirect. Research reports that MOTS-c interferes with the folate-methionine cycle, causing accumulation of AICAR, which activates AMPK (AMP-activated protein kinase), the enzyme that shifts cells from storing glucose toward oxidising fuel.

That is where the clock enters. AMPK activity is not flat across 24 hours. Work published in Science in 2009 described AMPK phosphorylating CRY1, a core clock protein, marking it for degradation, which wires cellular energy sensing directly into circadian timekeeping. NAD+, the cofactor sirtuins depend on, also oscillates daily, because NAMPT, the enzyme that recycles it, is transcriptionally controlled by CLOCK:BMAL1. Human glucose tolerance and insulin sensitivity follow their own diurnal curve.

So when researchers search for the best time to take MOTS-c, the variable they are chasing is not in the vial. What differs between windows is the host: substrate availability, mitochondrial membrane potential, AMPK tone, and clock-gene phase. Our team has worked with researchers running MOTS-c in metabolic models, and the ones who generate clean, reproducible data treat time-of-day the way they treat fasting duration. It goes in the methods section as a fixed condition, not an afterthought.

What the literature says about the best time to take MOTS-c

No published study has directly compared morning against night administration of MOTS-c in humans, and that absence is the honest starting point for the entire MOTS-c morning or night discussion. What the animal literature offers instead is timing expressed in Zeitgeber time (ZT), where ZT0 marks lights-on in the animal facility and ZT12 marks lights-off.

Here is the detail nearly every consumer-facing article about MOTS-c in the morning or night misses. Rodents are nocturnal. Most handling in a conventional vivarium happens during the light phase, a few hours after ZT0, because that is the researcher's working day. For the mouse, that is mid-sleep. A rodent experiment casually described as morning dosing is therefore closer, physiologically, to the middle of a human night, unless the facility runs a reversed light cycle, in which case ZT2 falls in the technician's afternoon. Two papers can both say morning and mean opposite circadian phases. That is the confound behind most of the confident internet answers about MOTS-c day or night.

Exercise compounds it. Reynolds and colleagues reported in Nature Communications in 2021 that MOTS-c expression rises with exercise in skeletal muscle, and exercise itself acts as a zeitgeber that shifts peripheral muscle clocks. In any model combining the two, administration time and exercise time are entangled variables.

Queries such as best time to inject MOTS-c peptide are requests for human protocol guidance, and no supplier should be answering them. Real Peptides supplies research-use-only material and provides no administration, timing, or preparation instructions.

Handling and identity decide whether a timing result means anything

A time-of-day experiment is only as trustworthy as the material in the vial. Lyophilised MOTS-c is stored at -20C, protected from light, and degrades fastest when the powder takes on moisture or a stock is repeatedly frozen and thawed. Peptide degradation does not announce itself. A partially hydrolysed 16-mer looks identical to an intact one, and the lost activity gets misread as a circadian effect when one arm of a study runs weeks after another.

Identity matters as much as stability. Before procurement, researchers should be verifying molecular identity and purity against a batch-specific certificate of analysis showing HPLC purity and mass spectrometry confirmation, not a generic document recycled across lots. Our MOTS-c 10mg is produced through small-batch synthesis with exact amino-acid sequencing, and every batch carries a publicly verifiable COA.

Being plain about scope: Real Peptides does not provide dosing or preparation guidance, because these are research-use-only compounds and those decisions belong to the qualified investigator writing the protocol. What we do speak to is the concentration framework, meaning the mass of peptide stated per vial on the certificate, which is the figure any mg-per-mL calculation starts from. Everything past that arithmetic is protocol territory.

In our experience supplying labs investigating the best time to take MOTS-c in rodent metabolic models, batch consistency across a long study is the quality variable that decides whether a timing signal survives analysis at all.

Morning versus night windows in MOTS-c research designs

Researchers asking about MOTS-c at night or morning are really comparing host metabolic states, not hours on a clock. This table maps the windows most often reported in the literature and what each implies for a design chasing the best time to take MOTS-c.

Timing window	Host metabolic state described in the literature	Study-design implication	Bottom line
Rodent early light phase (around ZT0 to ZT4)	Rest-phase onset in a nocturnal animal: falling activity, reduced feeding, shifting AMPK tone	Most convenient for staffing, but corresponds to human sleep, not human morning	Convenient, not translational. Label it rest-phase in the methods, never morning.
Rodent early dark phase (around ZT12 to ZT16)	Feeding onset and peak locomotor activity, highest substrate flux	Closest analogue to a human active phase, requires red-light handling and off-hours staffing	Better translational match, and worth the scheduling cost if circadian phase is the question.
Human active-phase morning, overnight fasted	Glucose tolerance generally highest early in the day, low circulating insulin after an overnight fast	Cleanest baseline for insulin sensitivity endpoints in observational work	The tidiest metabolic baseline, but no human MOTS-c timing trial exists to justify a recommendation.
Human evening	Declining glucose tolerance, larger post-prandial excursions, melatonin onset	Timing is confounded with the evening meal, activity, and sleep onset	Hardest window to interpret, because too many variables move at once.
Adjacent to an exercise bout	Exercise raises skeletal muscle MOTS-c expression and shifts peripheral muscle clocks	Administration time and exercise time become entangled variables	Never treat exercise-adjacent timing as a clean time-of-day comparison.

What If: MOTS-c Timing Scenarios

What if the animal facility light cycle cannot be controlled?

Record the facility lighting schedule in the methods and convert every administration and sampling point into Zeitgeber time before analysis. A shared vivarium running a fixed conventional cycle still permits a valid circadian comparison, provided all arms of the study are anchored to the same ZT reference and handling is clustered within a narrow window. What ruins the data is drift: one cohort handled at ZT2 and another at ZT7 across the same study, with both logged as morning. Clock time is the wrong unit for a nocturnal model.

What if two MOTS-c papers report opposite results at the same clock time?

Check the light cycle before assuming the findings conflict. A reverse-light-cycle facility's ZT2 falls in the technician's afternoon, so two experiments described identically in plain language can sit twelve hours apart in circadian phase. Fasting duration before administration is the second thing worth checking, since AMPK tone depends heavily on nutrient state. In our experience reviewing timing literature with research customers, apparent contradictions in mitochondrial peptide studies resolve at the methods section far more often than at the results.

What if exercise is part of the research model?

Treat exercise timing and administration timing as two separate variables and hold one constant while varying the other. Reynolds and colleagues reported that MOTS-c expression is exercise-responsive in skeletal muscle, and exercise also entrains peripheral muscle clocks independently of the central pacemaker in the suprachiasmatic nucleus. A design that moves both at once cannot attribute an effect to either. Endogenous expression changes also mean baseline MOTS-c is no longer a fixed quantity across the study.

What if a vial has been through several freeze-thaw cycles mid-study?

Document it, and consider whether that cohort remains comparable to earlier arms. Repeated freeze-thaw and moisture exposure drive peptide hydrolysis and aggregation, and neither is visible in a lyophilised cake. The practical risk is misattribution: reduced activity in a late-running arm reads as a circadian difference when it is actually a materials problem. Aliquoting stocks at receipt and working from a single synthesis batch across a long study protects the timing signal more effectively than any statistical correction applied afterward.

The uncomfortable truth about morning-versus-night MOTS-c claims

Let's be direct: every confident article telling you MOTS-c works better in the morning is extrapolating from AMPK chronobiology in rodents and presenting the guess as a finding. No human trial supports it. The mechanistic reasoning is genuinely interesting, and the circadian biology underneath it is real and well documented, but interesting reasoning is not evidence of an optimal hour. MOTS-c is not an FDA-approved drug, it is not for human or veterinary consumption, and it is supplied for laboratory research only. Anyone selling a timing protocol alongside it has stopped describing research and started writing marketing copy.

Researchers comparing formats and documentation can review our MOTS-c liquid spray, read the broader MOTS-c research overview, check batch documents on the certificates of analysis page, browse the full research peptide catalog, or see fulfilment details on our locations page.

The best time to take MOTS-c is, for now, an open question in the literature rather than a settled protocol, and the labs producing the most useful data are not trying to close it with a wall clock. They are recording Zeitgeber time, logging light cycles, fixing fasting state, and treating circadian phase as a condition worth reporting in full. That is the shift worth making. A timing question that looks like it needs an answer usually needs a better methods section, and mitochondrial peptides reward that discipline more than almost any other class of research compound.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Neither can be recommended. MOTS-c is a research-use-only compound, and Real Peptides provides no administration or timing guidance to individuals. Published research treats time-of-day as a study-design variable, because AMPK activity and NAD+ availability oscillate across 24 hours. Any human timing claim online is extrapolation, not trial evidence.

No supplier or article can answer that responsibly. MOTS-c is not an FDA-approved drug and is supplied strictly for laboratory research use. Circadian literature explains why timing matters mechanistically in animal models, but no published human trial has compared morning against night administration of MOTS-c.

There is no established answer. Rodent studies report administration in Zeitgeber time rather than clock time, and because rodents are nocturnal, a light-phase experiment corresponds to the animal's rest phase. That design detail makes cross-study timing comparisons unreliable unless light cycles are reported.

Timing belongs to the investigator's protocol, not to a supplier's recommendation. The literature reports that MOTS-c acts upstream of AMPK, whose activity follows a circadian rhythm linked to CRY1 degradation and NAD+ cycling, so published designs record time-of-day as a controlled experimental condition.

The MOTS-c morning or night comparison has not been resolved by any published head-to-head study. Research does describe substantial differences in host metabolic state between those windows, including fasting duration, substrate availability, and clock-gene phase, which is why careful designs fix and report administration time.

Real Peptides does not administer peptides or advise anyone on when to. We supply high-purity, research-grade MOTS-c to laboratories with batch-specific certificates of analysis. Questions about MOTS-c in morning or night conditions are answered by the investigator's protocol and their institutional review process.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide of roughly 2.2 kDa, encoded within the 12S rRNA region of mitochondrial DNA rather than the nuclear genome. It was first characterised in 2015 in Cell Metabolism by Pinchas Cohen's research group, with reported effects on the folate-methionine cycle and AMPK activation.

Real Peptides supplies MOTS-c to researchers, laboratories, and institutions for in-vitro and preclinical research use only. These compounds are not for human or veterinary consumption. Purchasers are responsible for confirming that their intended use complies with institutional policy and applicable regulations.

Pricing varies by vial size and format, and current pricing is listed on each product page. Every order includes access to a batch-specific certificate of analysis documenting HPLC purity and mass spectrometry identity confirmation, which is the document worth comparing before comparing prices between suppliers.

No. MOTS-c is not an FDA-approved drug and is not approved for the diagnosis, treatment, or prevention of any condition. It is supplied as a research compound for laboratory use. Any supplier describing MOTS-c as approved, or as a therapy, is misrepresenting its regulatory status.

MOTS-c belongs to a small family of peptides encoded in mitochondrial DNA that also includes humanin and the SHLP series. Research describes humanin largely in cytoprotection and apoptosis contexts, while MOTS-c work has focused on metabolic regulation, AMPK signalling, and exercise-responsive expression in skeletal muscle.

Zeitgeber time anchors an experiment to the light cycle, where ZT0 is lights-on, because laboratory animals entrain to facility lighting rather than the researcher's wall clock. Reporting ZT allows another lab to reproduce the circadian phase of the experiment even when its facility runs a reversed light cycle.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA